YIH
CTMX icon

Y-Intercept (HK)’s CytomX Therapeutics CTMX Stock Holding History

Y-Intercept (HK)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-167,514
Closed -$787K – 1789
2026
Q1 		$787K Buy
+167,514
New +$850K 0.01% 1113
2024
Q2 		– Sell
-55,595
Closed -$121K – 1485
2024
Q1 		$121K Buy
+55,595
New +$103K 0.01% 1257

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Y-Intercept (HK)'s CTMX Position: Q2 2026 in Review

Y-Intercept (HK) sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 167,514 shares — an estimated $787K sold.

Y-Intercept (HK) first reported a position in CTMX in Q1 2024 and held it in 2 quarters. The position peaked at $787K in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Y-Intercept (HK) reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 167,514 CytomX Therapeutics shares in Q2 2026, an estimated $787K.
  • Y-Intercept (HK) first reported a position in CytomX Therapeutics in Q1 2024 and held it in 2 quarters.
  • Y-Intercept (HK)'s CytomX Therapeutics position peaked at $787K in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.